McKesson Raises Full-Year Guidance Following 5.2% Q1 Earnings Beat

Key Facts

1McKesson reported adjusted EPS of $9.93 for Q1 fiscal 2027, beating consensus estimates by 5.2%.

2The company's revenue increased by 8% year-over-year to reach $105.38 billion.

3The company raised its full-year fiscal 2027 adjusted EPS guidance to a range of $44.20-$45.00.

In a move reflecting the healthcare sector's resilience against operational challenges, McKesson Corporation announced strong financial results for the first quarter of fiscal 2027. The company reported adjusted earnings per share (EPS) of $9.93, beating consensus estimates by 5.2%, while revenue grew 8% year-over-year to reach $105.38 billion. This performance comes despite reports of a recent cybersecurity incident involving third-party applications used by a subset of the company's oncology and multispecialty customers.

Following the robust quarterly performance, McKesson raised its full-year fiscal 2027 adjusted EPS guidance to a range of $44.20 to $45.00. Per market data, the company demonstrated significant operational strength, with revenue exceeding the $104.39 billion consensus estimate. Growth was notably supported by GLP-1 medication distribution revenue, which reached $15 billion, representing a 24% increase compared to the previous year.

McKesson (MCK) shares stood at $880.50 at the close of September 23, 2026, as investors weigh the upgraded guidance against recent market volatility. The stock reached a daily high of $907.07 during the session before settling at the closing level. Market participants should look ahead to November 4, 2026, when the company is scheduled to release its second-quarter fiscal 2027 results after the market close.